| 000 | 01838 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516051254.0 | ||
| 264 | 0 | _c20120404 | |
| 008 | 201204s 0 0 eng d | ||
| 022 | _a1539-2864 | ||
| 024 | 7 |
_a10.1097/IAE.0b013e318225290f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPark, Dong Ho | |
| 245 | 0 | 0 |
_aLOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy. _h[electronic resource] |
| 260 |
_bRetina (Philadelphia, Pa.) _cFeb 2012 |
||
| 300 |
_a299-307 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aChoroid Diseases _xdrug therapy |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHigh-Temperature Requirement A Serine Peptidase 1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeripheral Vascular Diseases _xdrug therapy |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPhotochemotherapy |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 |
_aPolyps _xdrug therapy |
| 650 | 0 | 4 |
_aProteins _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aSerine Endopeptidases _xgenetics |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 700 | 1 | _aKim, In Taek | |
| 773 | 0 |
_tRetina (Philadelphia, Pa.) _gvol. 32 _gno. 2 _gp. 299-307 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/IAE.0b013e318225290f _zAvailable from publisher's website |
| 999 |
_c21062999 _d21062999 |
||